We previously reported that natural killer cell stimulatory factor (NKSF), a heterodimeric lymphokine purified from the conditioned medium of human B lymphoblastoid cell lines, induces interferon y (IFN-y) production from resting peripheral blood lymphocytes (PBL) and synergizes with interleukin 2 in this activity. In this study, we show that human NKSF induces IFN-y production from both resting and activated human PBL and from freshly isolated murine splenocytes . Human T and NK cells produce IFN-,y in response to NKSF, but resting PBL require the presence of nonadherent human histocompatibility leukocyte antigens DR' (HLA DR+) accessory cells to respond to NKSF. The mechanism(s) by which NKSF induces IFN-y production results in accumulation of IFN-y mRNA, is insensitive to cyclosporin A, and synergizes with those mediated by phytohemmagglutinin, phorbol diesters, anti-CD3 antibodies, and allogeneic antigens, but not by Ca 2+ ionophores. The ability of NKSF to directly induce IFN-,y production and to synergize with other physiological IFN-,y inducers, joined with the previously described ability to enhance lymphocyte cytotoxicity and proliferation, indicates that this lymphokine is a powerful immunopotentiating agent .
Summary
We previously reported that natural killer cell stimulatory factor (NKSF), a heterodimeric lymphokine purified from the conditioned medium of human B lymphoblastoid cell lines, induces interferon y (IFN-y) production from resting peripheral blood lymphocytes (PBL) and synergizes with interleukin 2 in this activity. In this study, we show that human NKSF induces IFN-y production from both resting and activated human PBL and from freshly isolated murine splenocytes . Human T and NK cells produce IFN-,y in response to NKSF, but resting PBL require the presence of nonadherent human histocompatibility leukocyte antigens DR' (HLA DR+) accessory cells to respond to NKSF. The mechanism(s) by which NKSF induces IFN-y production results in accumulation of IFN-y mRNA, is insensitive to cyclosporin A, and synergizes with those mediated by phytohemmagglutinin, phorbol diesters, anti-CD3 antibodies, and allogeneic antigens, but not by Ca 2+ ionophores. The ability of NKSF to directly induce IFN-,y production and to synergize with other physiological IFN-,y inducers, joined with the previously described ability to enhance lymphocyte cytotoxicity and proliferation, indicates that this lymphokine is a powerful immunopotentiating agent . N atural killer cell stimulatory factor (NKSF)' is a cytokine that was identified and purified from the conditioned medium of B lymphoblastoid cell lines. The NKSF protein is a 70-kD disulfide-linked heterodimer composed of a MAD and a 40-kD chain. NKSF induces IFN-,y production from PBLs, augments NK cell-mediated cytotoxicity, and enhances T cell proliferation induced by lectins and phorbol diesters (1) . We have cloned and sequenced the two genes encoding NKSF and have shown that the biological activity of recombinant NKSF is identical to those we reported for purified natural NKSF, confirming that NKSF is a novel cytokine (1a) . Recently, cytotoxic lymphocyte maturation factor (CLMF) was purified by Stern et al. (2) from the con-' Abbreviations used in this paper . CLMF, cytotoxic lymphocyte maturation factor ; C&A, cyclosporin A ; EMC, encephalomyocarditis; F/H, FicollHypaque; LT, lymphotoxin; MLC, mixed leukocyte culture; NKSF, natural killer cell stimulatory factor ; PDBu, phorbol dibutyrate ; PKC, protein kinase C ; TPA, tetradecancylphorbol acetate. ditioned medium of the human B lymphoblastoid cell line NC-37; this factor appears to have physicochemical characteristics, biological activity, and NH2-terminal amino acid sequences identical to those of NKSF.
Regulation of IFN-,y production during inflammation or an immune response is of central importance to the mechanisms ofboth adaptive and nonadaptive resistance (3-6) . Thus, the ability of NKSF to induce IFN-y production from PBL may represent one of the most biologically significant functions of this lymphokine. IFN-,y is not constitutively produced by resting PBL . However, both NK and T cells are induced to secrete IFN-y in response to 1172 stimulation (7-9) . NKSF synergizes with IL-2 in inducing IFN-,y production from PBL (1) . T cells also produce IFN-,y upon specific ligand interaction with TCR (7) ; this interaction can be partly replaced by antibodies to TCR or to the TCR associated CD3 complex (10) . NK cells produce IFN-y upon crosslinking of the type III receptor for Fc of IgG (FcyRIII or CD16) (11) . Similar to NKSF, TCR-CD3 and CD161igands syner-gize with IIr2 to induce IFN-y production from T and NK cells, respectively. The effect of these IFN-y inducers can be mimicked by lectins such as PHA (12) (13) (14) , by phorbol diesters (12, 15, 16) , and by Caz+ ionophores (17, 18) .
In this study, we have characterized the IFN-y-inducing activity of NKSF and compared it to other inducers of IFN-y. We report that human NKSF induces IFN-y production from resting and activated human T and NK cells, as well as from mouse lymphocytes. NKSF-induced IFN-y production in human PBL is mediated via a mechanism that is insensitive to cyclosporin A (CsA), synergizes with several other IFN-y inducers, and requires the participation of nonadherent HLA DR+ accessory cells.
Materials and Methods
Cytokines and Reagents . rID2 (10' U/mg) was generously provided by Dr. T Taguchi (Osaka University, Osaka, Japan) and Takeda Chemical Industrial Industry, Inc. (Osaka, Japan) . The following reagents were purchased from commercial sources: PHA-M (Wellcome Diagnostics, Dartford, England) ; 12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma Chemical Co ., St . Louis, MO); phorbol-12,13-dibutyrate (PDBu; Chemsyn Science Laboratories, Lexena, KS); Cal+ ionophore A23187 (Sigma Chemical Co., St . Louis, MO); cyclosporin A (C&A ; Sandoz Ltd., Vienna, Austria) .
Preparations ofNKSF. NKSF was purified as described in detail by Kobayashi et al . (1) from serum-free conditioned medium of 48-h PDBu-induced RPMI 8866 cell cultures. The IFN-y induction assay (described below) was used to quantitate NKSF activity in semi-purified and purified preparations. 1 U of NKSF activity is defined as the amount required to induce half-maximal IFN-y production . The purified NKSF preparation used in this study had a specific activity of 4 x 106 U/mg protein. In many of the experiments described, we used semi-purified preparations of NKSF obtained after a two-step purification procedure: (a) hydroxylapatite chromatography and (b) Mono Q ion exchange chromatography performed as previously described (1).
Antibodies. mAbs B36.1(anti-CD5, IgG2b), B67.1(anti-CD2, IgG2a), B73.1(anti-CD16, IgGl); B52.1(anti-CD14, IgM) ; B33.1 (anti-HLADR, nonpolymorphic determinant, IgG2a) ; B133 .1 and B133 .5 (anti-IFN-y, IgGl) were produced and characterized in our laboratory. Antibody OKT3 (anti-CD3, IgG2a) was produced from hybrid cells purchased from American Type Culture Collection (ATCC) (Rockville, MD) and antibody 3G8 (anti-CD16, IgGl) was kindly provided by Dr. J. Unkeless (Mount Sinai School of Medicine, New York, NY). Culture supernatants or antibodies purified from ascitic fluids were used at predetermined optimal concentrations. Goat anti-IL2 antiserum (>10 5 neutralizing U/ml) and the affinity-purified goat anti-mouse IgG were produced in our laboratory An NKSF neutralizing antiserum was obtained from a rabbit immunized with the purified recombinant 40-kD chain of NKSF. FITC-labeled goat F(ab')2 anti-mouse Ig was purchased from Cappel Laboratories (Cochranville, PA) and used after adsorption to human IgG.
Cell Preparations. Peripheral blood was obtained by venipuncture from adult healthy donors using heparin as anticoagulant. PBMC were separated on Ficoll-Hypaque (F/H) density gradient (Lymphoprep; Nyegaard and Co., Oslo, Norway). PBL were prepared from PBMC after partial depletion of monocytes by adherence to plastic (45 min, 37°C) . Different PBL subsets and accessory cells were purified from the PBL preparations by (a) positive and negative selection, as indicated, using mAbs specific for leuko-
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Interferon y Induction by Natural Killer Cell Stimulatory Factor cyte differentiation antigens, indirect antiglobulin rosetting, and F/H gradient separation, as described (19) 4 , was incubated overnight at 4°C in flat-bottomed bacteriological %-well microtiter plates ; the wells were washed three times with PBS immediately before the different leukocyte preparations were added and the plates incubated (37°C, 5% CO 2, 18 h) . After incubation, triplicate 50 pl of cell-free supernatant was collected from each well and IFN-y was measured as described below.
Human Mixed Leukocyte Culture (MLC). 5 x 104 responder PBMC were mixed with 105 irradiated (45 Gy) stimulator PBMC from autologous or unrelated allogeneic donors in 200 icl of RPMI 1640 supplemented with 10% heat-inactivated human AB serum in round-bottomed microtiter plates . After 6 d of incubation at 37°C, cell-free supernatant fluids were collected and IFN-y was measured by RIA.
IFN Assays. RIA for human IFN-y was performed as previously described (22) . Sensitivity of the assay is 0.5 U/ml IFN-y and no crossreaction with TNF, lymphotoxin (LT), or other species of IFN is observed. Murine IFN-y was measured using a commercial ELISA (Amgen, Thousand Oaks, CA): sensitivity of the assay is 12 U/ml IFN-y . Antiviral activity in the cell-free supernatants of murine cell cultures was assessed by inhibition of the cytopathic effect of encephalomyocarditis (EMC) virus on the mouse fibroblast cell line, LF2, as described (23) ; assays were quantitated using the NIH mouse IFN reference as standard.
In Situ Hybridization. Cell preparations were deposed on microscope slides using a cytocentrifuge. 3'S-labeled riboprobes were prepared from plasmids containing a 5' 80-bp fragment of the human IFN-y cDNA inserted into the PstI restriction site of the pGem3 vector. Plasmids were linearized at the EcoRl and HindIII restriction sites and transcribed into mRNA-complementary (antisense) and mRNAlike (sense) probes using IIS-UTP (New England Nuclear, Wilmington, DE) and a riboprobe kit (Promega Biotec, Madison, WI) according to the manufacturer's suggestions. Hybridization was carried out overnight at 45°C as described by Harper et al. (24) . Slides were washed twice (10 min at room temperature) in 2 x SSC (lx = 0.15 M NaCl, 0.015 M NaCitrate, pH 7.0) and four times (15 min, 55°C) in 0.25X SSC,1 mM EDTA,1 mM DTT Nonhybridized probe was digested with 40 FAg/ml RNase A (Sigma Chemical Co.) in 10 mM tris, pH 8, 0.3 M NaCl for 30 min at 37°C. The slides were then washed (30 min, 55°C) twice in 50% formamide, 2x SSC, 1 mM DTT, and finally, in 2x SSC, 1 mM DTT After dehydration in graded ethanol solutions containing 0.3 M ammonium acetate and air drying, the slides were dipped in NTB3 nuclear track emulsion (Eastman Kodak Co., Rochester, NY) diluted 1:1 with 0.6 M ammonium acetate. After exposure for 3-7 d at 4°C, the slides were developed with Kodak D-19 developer, fixed with Kodak Rapidfix, and counterstained with hematoxylin and eosin .
Northern Blot Hybridization . Cytoplasmic RNA samples were prepared from induced and uninduced cells using the NP-40 1ysis method as described (25) . RNA samples were fractionated in a 1% agarose-formaldehyde gel. Briefly, the fractionated RNA was transferred to nylon membrane filters (Schleicher & Schuell, Inc., Keene, NH) by capillary action and crosslinked to filters by UV irradiation. The human IFN-,y cDNA probe (restriction fragment at the Pstl site from a construct in pSWIF) and the human ß-actin cDNA probe in pBR322 (grown in plasmid form, kindly provided by Dr. Roberto Weinmann, Wistar Institute), were labeled with 'zPcxCTP (-3000 Ci/mmol ; New England Nuclear) using a random priming kit (Amersham Corp., Arlington Heights, IL) . Filter-bound RNA was hybridized according to Singh and Jones (26) at 42°C for 16 h with labeled probe at 1-2 x 106 cpm/ml hybridization solution: 4x SET (0.1 M NaCl, 6 mM tris-Cl, pH 7.5, 0.4 mM EDTA, pH 7.4), 0.1% sodium pyrophosphate, 0.2% SDS, 10% dextran sulfate, 500 FAg/ml heparin sodium salt grade II from porcine intestinal mucosa (Elkins-Sinn, Inc., Cherry Hill, NJ), and 100 tcg/ml denatured salmon sperm DNA. After hybridization, the filters were washed three times at 37°C with 2x SSC, 0.1% SDS, once at 65°C with O.1x SSC, 0.1% SDS for 45 min, and then exposed to X-Ornat AR film (Eastman Kodak Co.) between double intensifying screens (DuPont Co., Wilmington, DE) at -70°C.
Results
IFN--y Production by PBL Induced with NKSF. We (1) previously reported that purified NKSF induces IFN--y production in freshly isolated PBL in a dose-dependent manner and synergizes with rIL2 in this activity. To determine if NKSF synergizes with other inducers ofIFN-y, PBL were incubated (18 h) with increasing concentrations of purified NKSF in the absence or presence of PHA, phorbol diesters, Ca 2+ ionophores, or anti-CD3 (OKT3) antibodies; IFN-y was quantitated by RIA in the cell-free supernatants . NKSF, in a dose-dependent manner, synergized with PHA ( Fig. 1 A) , the phorbol diesters TPA (Fig. 1 B) and PDBu (not shown), and anti-CD3 antibodies ( Fig. 1 C) at all concentrations tested, to induce IFN-y secretion . rIL2, which synergizes with NKSF in inducing IFN--y production, did not synergize with PHA or phorbol diesters (not shown) . The Ca 2+ ionophores, A23187 (Fig. 1 D) and ionomycin (not shown), efficiently synergized with phorbol diesters in inducing IFN--y production, but the same concentrations did not synergize with NSKF and inhibited IFN--y production induced with high NKSF concentrations.
To determine whether PHA or TPA synergizes with NKSF via the induction of íL2 production, PBL were stimulated with NKSF, alone, or in combination with PHA or TPA,
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Chan et al. in the presence of a goat anti-IIr2 antiserum (Fig. 2) . The antiserum completely suppressed IFNJy production in response to 100 U/ml of rIL2 and partially (22%), but significantly reduced IFN-y production induced by NKSF alone. IFN-y production in response to NKSF and rIL2 was inhibited to the levels observed with NKSF alone. No inhibition ofIFN--y production by anti-í1r2 antiserum was observed when PBL were stimulated with PHA, with or without NKSF, or with phorbol diesters plus NKSF. However, significant inhibition was observed when PBL were stimulated by phorbol diesters alone. Preimmune goat serum did not inhibit IFN-y production induced by any of the stimuli used (not shown) . To determine whether CSA, which suppresses anti-CD3 and lectin-induced IFN--y and 11,2 production (27) in T cells, affects NKSF-induced IFN-y production, PBL were stimulated with NKSF and other stimuli in the presence of CsA . As expected, CsA (1 hg/ml) significantly inhibited IFN-y production in PBL stimulated with anti-CD3 (OKT3) antibodies but not with rIL 2 (Table 1) . At the same concentration, CsA did not inhibit IFN--y production induced by NKSF with or without rIL2 (Table 1) , but partially inhibited IFN-y production induced by PHA or TPA, alone or in synergy with NKSF (not shown) .
Neutralization ofIFN-y-inducing Activity by Rabbit Antiserum Against Recombinant NKSF. Results in Table 2 show that a 1:160 dilution of the anti-40-kD chain antiserum completely blocks the IFN--y production induced by semi-purified NKSF, alone or in synergy with rIL2, without significantly affecting PBL were incubated for 18 h at 37°C with 2.5 U/ml semi-purified NKSF alone or in combination with 100 U/ml rIIJ2, 10 ug/ml PHA, or 10 -7 M PDBu in the absence (solid bars) or in the presence (hatched ban) of a 1/100 dilution of goat anti-human 11,2 antiserum. IFN-y production was measured by RIA. Results are expressed as mean ± SE of results obtained with n different donors . p values (IFN-y production in cultures in the absence versus presence of anti-IIb2) were calculated using the Student t test.
IFN-y production induced by rIL2 . Preimmune serum had no effect. These results show that NKSF is the only factor with IFN-y-inducing activity present in the semipurified preparations of NKSF. 
Requirement ofAccessory Cells for IFN-y Production by PBL in Response to NKSF. Plastic adherent PBMC, total nonadherent PBL, and the HLADR+ and DR -PBL populations prepared by indirect rosetting were cultured with increasing concentrations of NKSF. As shown in Fig. 3 , similar levels of IFN-y were produced by PBL or by PBL depleted of monocytes after a second adherence or by removal of CD14+ cells. PBL depleted of HLADR+ cells produced significantly lower levels of INF-y, but removal of CD20+, CD21+ B cells from PBL did not result in decreased IFN-y production in response to NKSF (not shown) . Adherent cells, containing >90% CD14+ monocytes (28) , were unable to reconstitute IFN-y production (Fig . 3) . IFN-y production was restored Production of IFN-y in Human MLC in the Presence of NKSF. NKSF was added to MLC at the beginning ofculture and IFN-y in the supernatants was measured after 6 d (Fig. 4) . In the absence of added NKSF, cultures stimulated by allogeneic but not autologous cells produced IFN-y at levels lower than 40 U/ml. In the presence of NKSF, allogeneic cultures produced between 300 and 1,000 U/ml of IFN-'y, whereas autologous cultures produced no more than 30 U/ml of IFN-y. In addition, when cells collected from a primary MLC at day 14 were restimulated with the specific allogeneic cells in a secondary MLC, INF-y production in cultures stimulated in the presence of NKSF were higher than in control cultures (not shown) .
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Chan et al. IFN--y Production by Peripheral Blood Tand NK Cells Stimulated with NKSF. Preparations enriched in T and NK cells were obtained from PBL by positive or negative selection using anti-CD3 or anti-CD16 antibodies and indirect rosetting. The cells were stimulated with NKSF, alone or in combination with rIL2. Positively selected cells with either antibody were poor producers of IFN-y, probably because of the absence of accessory cells in the preparations. However, when HLA DR+ accessory cells were added to the enriched cell preparations, similar levels of IFN-y were detected in both the enriched T (CD3+ or CD16 -) and NK cell (CD3 -or CD16+) preparations (not shown) .
IFN-y production in PBL was analyzed at the single cell level by in situ hybridization . Total PBL were stimulated for 18 h with NKSF, rIL2, or NKSF plus rIL 2. CD3 + or CD3 -and CD16+ or CD16 -cell populations were separated by fluorescence activated cell sorting after staining by indirect immunofluorescence with antibodies OKT3 and 3G8, respectively. Accumulation of IFN-y mRNA in these populations was analyzed by in situ hybridization ( Cells were cultured (5 x 106/ml, 200 Al/well) with the indicated inducers for 18 h at 37°C, and IFN-7 in the cell-free supernatant fluid was quantitated by RIA. t T cells (CD16 -, CD56-, CD14 -) and NK cells (CD3-, CD5 -, CD14-) were purified using indirect antiglobulin rosetting and gradient centrifugation from 10-d culture of PBL stimulated with irradiated RPMI 8866 cells . T cells preparation were >95% pure and NK cell preparation >98% pure. S Mean ± SD of three experiments .
mRNA was detected in a small proportion of T and NK cells induced with NKSF or rIIr2 ( Table 3) . The number of positive cells (> 10 grains per cell) in cultures treated with NKSF or rIL2 alone ranged from 1.5 to 6.5% ; the number of positive cells detected in cultures from both cell types treated with NKSF plus rIL2 ranged from 7.5 to 16% . In addition, the highly positive cells in cultures stimulated with NKSF and rIL2 contained a much greater number of grains than the highly positive cells in cultures stimulated with NKSF or rIL2 alone (not shown) .
Lastly, IFN-y production was measured in T and NK cell preparations purified from 10-d cocultures of PBL with the irradiated B lymphoblastoid cell line, RPMI-8866 ; these populations were treated with NKSF, in the absence or presence of rIL2, for 18 h. As shown in Table 4 , both T'and NK cells produced IFN-y in response to NKSF and/or rIL2 stimulation.
IFNq mRNA Accumulation in PBL andPHA-activatedBlasts Stimulated with NKSF. To determine if resting and activated lymphocytes respond to NKSF with the same kinetics, we tested the ability of NKSF to induce IFN-y in PBL versus PHA activated T cell blasts. PHA blasts contain >98% CD3+ T cells with variable proportions of CD4' and C138' cells, as detected by indirect immunofluorescence. More than 90% of these cells are CD25+, CD71+, and HLADR+ (not shown) ; PHA blasts do not proliferate but accumulate in the G1 phase of the cell cycle after 5 d in culture. However, they are rapidly induced to proliferate in response to IL2 (not shown) .
PBL and PHA blasts were stimulated for 1, 2, 4, and 24 h in the presence of NKSF and/or rIL2. Cytoplasmic RNA, extracted at each time point, was probed for IFN-y mRNA by Northern blot hybridization and IFN-y was measured in Table 5 . NKSF the cell-free supernatant fluids of the 24-h cultures . NKSF, alone or in combination with rIL 2, induced PHA blasts to secrete IFN-y albeit at consistently lower levels than observed with PBL (Fig. 5 A) . Both PBL and PHA blasts accumulated IFN-y mRNA in response to NKSF and/or rIL2 stimulation, although the activated cells displayed significantly earlier kinetics of mRNA accumulation than PBL (Fig. 5  A) . On average, IFN-y mRNA was detectable in PHA blasts after 1 h of stimulation and reached peak levels 4-8 h postinduction whereas maximal levels of IFN-y mRNA were detected in PBL after 24-h culture . Identical results were obtained in PHA blasts using purified (Fig. 5 B) NKSF at 4 h of induction .
IFN-y Production by Human NKSRtreated Mouse Lymphocytes. To test whether human NKSF is effective across species barriers on mouse lymphocytes, total splenocytes and spleen cells depleted of surface Ig+ (sIg+)-B cells by antiglobulin indirect rosetting and density gradient were obtained from adult BALB/c mice and incubated for 18 h with increasing concentrations of human NKSF, alone or in combination with 1,000 U/ml of human rIL2. The supernatants were tested for antiviral activity, as measured by inhibition of the cytolytic effect of EMC virus on mouse fibroblast LF2 cells (Table 5 ) and for IFN-y concentration by ELISA (not shown) . NKSF induced antiviral activity and IFN-y production by both total and sIg -splenocytes in a dose-dependent manner and synergized with rIL2 in this effect.
NKSF" rIL-2 (10' U/ml) and PHA blasts (dottedban) were incubated with 2 .5 U/ml semi-purified NKSF, 100 U/ml rIIT2, or NKSF plus rIIr2 . Cell-free supernatants were assayed for IFN-y by RIA . (Bottom panel) RNA were extracted from cells at various time points after incubation with NKSF and/or rIIT2 and analyzed by Northern blot using a cDNA probe for human IFN-y . (B) PHA blasts (5 x 106/ml) were stimulated for 18 h with 1 .25 U/ml purified NKSF, 100 U/ml rIL2, or NKSF plus rIL2 . Cell-free supernatants were assayed for IFN-y production by RIA . Cytoplasmic RNA were analyzed by Northern blot .
Discussion
The possibility that human B lymphoblastoid cell lines produce factor(s) affecting lymphocyte functions was suggested by their ability to facilitate IL2-dependent proliferation of both T and NK cells in vitro (29) (30) (31) . During studies in which lymphotoadn production by these cell lines was characterized (22), we identified a novel cytokine that we defined NKSF (1) . NKSF was purified 9,200-fold to near homogeneity from the supernatant fluid of phorbol diester-induced cells of the EBV transformed human lymphoblastoid cell line, RPMI 8866, on the basis of its ability to induce IFN-y production by human PBL (1) .
NKSF, when added to freshly isolated nonadherent PBL in an 18-h culture, induces IFN-y production in a dosedependent manner that is only partially inhibited (22% on average) by anti-IL-2 antiserum . In addition, as reported ear- 875 Chan et al .
lier, NKSF strongly synergizes with 11,2 in inducing IFN-y at all concentrations of rIL2 tested (1) . These observations exclude the possibility that IFN-y is indirectly induced by NKSF via the induction of IL2. Since IFN-y production induced by NKSF was partially inhibited by anti-IIr2 antiserum, this inhibition is probably due to minimal concentrations of 11,2 produced constitutively by PBL which enhances the IFN-y production induced by NKSF. We did not detect significant IL-2 message by standard Northern blotting techniques in induced and uninduced lymphocytes. NKSF also synergizes with other IFN-T inducers such as PHA and phorbol diesters; the quantities of IFN-y induced in these cultures range between 3-10-fold over levels expected for an additive effect . In addition, endogenously produced IL2 does not appear to be responsible for this synergy. However, a partial inhibition of the phorbol diester-induced IFN-y production by anti-IL2 antiserurn suggests that IIr2 production may play some role in inducing IFN-y production in these cultures . Solid-phase linked anti-CD3 antibodies induce IFN-y production in PBL and this effect is synergistic with NKSF during an 18-h culture. The ability of NKSF to synergize with signals transduced through the TCR is also indicated by the powerful enhancement of IFN-y production observed in allogeneic but not in autologous MLC in the presence of NKSF. A signal transduction pathway activated through TCR CD3 results in increased [Ca 2
and protein kinase C (PKC) activation (32) . The Ca2+ ionophores, A23187 and ionomycin, which are strongly synergistic with phorbol diesters (33), do not synergize with NKSF, suggesting that mechanisms other than increased [Ca 2 +]i are responsible for the synergistic effect ofTCRCD3 stimulation with NKSF. Since anti-CD3 antibodies, antigens, and PHA (34) act via the TCR CD3 complex, and phorbol diesters activate PKC (35), a major mechanism by which these inducers synergize with NKSF may be through activation of PKC. The mechanism of synergy between NKSF and I1r2 is, however, probably dependent on other pathways of signal transduction . Indeed, we (Chan, S.H., M. Kobayashi, D. Santoli, B. Perussia, and G. Trinchieri, manuscript submitted for publication) have observed major differences in the molecular mechanisms bywhich 11,2 and phorbol diesters synergize with NKSF in inducing IFN-y.
CsA has been proposed to suppress early events governing T cell activation, such as IL2 transcription, by inhibiting the activity of DNA binding proteins in response to antigen receptor triggering (27) . C&A does not inhibit IFN-y production by PBL induced with NKSF or 1172, alone or in combination, but almost completely abolishes the IFN-y production induced by anti-CD3 and partially inhibits the IFN-y production induced by PHA or phorbol diester, as well as the synergy between NKSF and these inducers. Taken together, these results suggest that NKSF functions through a different cell surface receptor and intracellular signal transduction pathway than each ofthe inducers tested . The ability of human NKSF to induce IFN-y production by murine splenocytes suggests that receptors crossreacting with the human cytokine are also present on murine lymphocytes.
Previous studies have shown that T and NK cells are the only producers of IFN-y during an immune response (7-9). NKSF induces IFN-y from both T and NK cells and synergizes with rIlr2 in both cell types. To mediate this activity on fresh PBL, NKSF requires the presence of nonadherent HLA-DR' accessory cells . If HLADR-cells are reconstituted with HLA-DR+ cells, which do not make IFN-y, they become responsive to NKSF. The accessory cells are not monocytes because monocyte-depleted cells can still respond to NKSF and HLA-DR -cells reconstituted with adherent monocytes do not produce IFN-y when stimulated with NKSF. This observation is consistent with those by others (36) (37) (38) (39) (40) (41) NKSF induces IFN-y production in both T and NK cells, as clearly shown by the results obtained using enriched and purified preparations of the two cell types from both fresh and cultured PBL . The results of in situ hybridization performed on T (CD3+ CD16-) and NK (CD3-CD16+) cells, positively and negatively selected from PBL after stimulation with NKSF and/or 11,2, confirm the ability ofboth cell types to respond to NSKF. T and NK cells stimulated with NKSF plus IL2 contain much higher numbers of grains per cell than cells stimulated with either cytokine alone, suggesting that synergy between NKSF and IL2 is largely due to the synergistic accumulation of IFN-y mRNA in individual cells. A higher number of cells accumulating IFN-y mRNA is observed, however, in samples stimulated with both inducers than with one alone. This observation may depend on the sensitivity of the detection system which may not have detected cells expressing very low levels of IFN-y mRNA in cells induced with one lymphokine alone.
The observation, by in situ hybridization analysis, that <20% ofPBL accumulate detectable levels of IFN-y mRNA in response to NKSF and/or IL2, suggests that only a small proportion of PBL are induced to accumulate mRNA and secrete IFN-y at a given time. Our results are consistent with those of Wilson et al. (41) , who demonstrated through immunofluorescent staining for IFN-y that only 5 to 20% of normal lymphocytes synthesize IFN-y in primary cultures with rIIr2 . Qui et al. (13) also showed that <20% ofPBMC accumulated IFN-y mRNA when stimulated with different stimuli, as detected by in situ hybridization . The observation that only a small proportion of lymphocytes respond to different stimuli with IFN-y production is difficult to explain. At present, no specific subset of human T and NK cells has been demonstrated to preferentially produce IFN-y . The small proportion of IFN-y-producing cells may be due to discrete PBL subsets which express receptors for the various IFN-y inducers, a heterogeneity in the ability of PBL to express receptors or to produce IFN-y, or a proportion of activated lymphocytes present in PBL which either express increased numbers of receptors or an increased efficiency in IFN-y production. The latter possibility is unlikely, however, because similarly small proportions of IFN-y-producing cells were detected by in situ hybridization of PHA-activated blasts stimulated with NKSF and IIr2 (our unpublished observation) .
